Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-9290357e39a2371931091ec451b2e152",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-9290357e39a2371931091ec451b2e152",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-9290357e39a2371931091ec451b2e152",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-9290357e39a2371931091ec451b2e152\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-9290357e39a2371931091ec451b2e152</b></p><a name=\"composition-en-9290357e39a2371931091ec451b2e152\"> </a><a name=\"hccomposition-en-9290357e39a2371931091ec451b2e152\"> </a><a name=\"composition-en-9290357e39a2371931091ec451b2e152-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/393/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - soliris</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/07/393/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp9290357e39a2371931091ec451b2e152"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - soliris",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet:</p><ol type=\"1\"><li>What Soliris is and what it is used for</li><li>What you need to know before you use Soliris</li><li>How to use Soliris</li><li>Possible side effects</li><li>How to store Soliris</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What soliris is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What soliris is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is Soliris Soliris contains the active substance eculizumab and it belongs to a class of medicines called monoclonal antibodies. Eculizumab binds to and inhibits a specific protein in the body that causes inflammation and so prevents your body s systems from attacking and destroying vulnerable blood cells, kidneys, muscles or eye nerves and spinal cord.</p><p>What is Soliris used for Paroxysmal Nocturnal Haemoglobinuria Soliris is used to treat adults and children patients with a certain type of disease affecting the blood system called Paroxysmal Nocturnal Haemoglobinuria (PNH). In patients with PNH, their red blood cells can be destroyed which can lead to low blood counts (anaemia), tiredness, difficulty in functioning, pain, dark urine, shortness of breath, and blood clots. Eculizumab can block the body s inflammatory response, and its ability to attack and destroy its own vulnerable PNH blood cells.</p><p>Atypical Haemolytic Uremic Syndrome Soliris is also used to treat adults and children patients with a certain type of disease affecting the blood system and kidney called atypical Haemolytic Uremic Syndrome (aHUS). In patients with aHUS, their kidney and blood cells, including platelets, can be inflamed which can lead to low blood counts (thrombocytopenia and anaemia), reduced or lost kidney function, blood clots, tiredness and difficulty in functioning. Eculizumab can block the body s inflammatory response, and its ability to attack and destroy its own vulnerable blood and kidney cells.</p><p>Refractory Generalized Myasthenia Gravis Soliris is also used to treat adult and children patients aged 6 years and above with a certain type of disease affecting the muscles and called generalized Myasthenia Gravis (gMG). In patients with gMG, their muscles can be attacked and damaged by the immune system which can lead to profound muscle weakness, impaired mobility, shortness of breath, extreme fatigue, risk for aspiration, and markedly impaired activities of daily living. Soliris can block the body s inflammatory response, and its ability to attack and destroy its own muscles to improve muscle contraction, thereby reducing symptoms of the disease and impact of the disease on the activities of daily living. Soliris is specifically indicated for patients who remain symptomatic despite treatment with other existing MG therapies.</p><p>Neuromyelitis Optica Spectrum Disorders Soliris is also used to treat adult patients with a certain type of disease that predominantly affects the eye nerves and the spinal cord called Neuromyelitis Optica Spectrum Disorder (NMOSD). In patients with NMOSD, their eye nerve and spinal cord are attacked and damaged by the immune system which can lead to blindness in one or both eyes, weakness or paralysis in the legs or arms, painful spasms, loss of sensation, and markedly impaired activities of daily living. Soliris can block the body s inflammatory response, and its ability to attack and destroy its own eye nerves and spinal cord, thereby reducing symptoms of the disease and impact of the disease on the activities of daily living.</p></div>"
}
},
{
"title" : "2. What you need to know before you take soliris",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take soliris"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not use Soliris</p><ul><li>If you are allergic to eculizumab, proteins derived from mouse products, other monoclonal antibodies, or any of the other ingredients of this medicine (listed in section 6).</li><li>If you have not been vaccinated against meningococcal infection unless you take antibiotics to reduce the risk of infection until 2 weeks after you have been vaccinated .</li><li>If you have a meningococcal infection.</li></ul><p>Warnings and precautions</p><p>Meningococcal and other Neisseria infections alert Soliris treatment may reduce your natural resistance to infections, especially against certain organisms that cause meningococcal infection (severe infection of the linings of the brain and sepsis) and other Neisseria infections including disseminated gonorrhea.</p><p>Consult your doctor before you take Soliris to be sure that you receive vaccination against Neisseria meningitidis, an organism that causes meningococcal infection, at least 2 weeks before beginning therapy, or that you take antibiotics to reduce the risk of infection until 2 weeks after you have been vaccinated. Ensure that your current meningococcal vaccination is up to date. You should also be aware that vaccination may not prevent this type of infection. In accordance with national recommendations, your doctor might consider that you need supplementary measures to prevent infection.</p><p>If you are at risk of gonorrhoea, ask your doctor or pharmacist for advice before using this medicine.</p><p>Meningococcal infection symptoms Because of the importance of rapidly identifying and treating certain types of infection in patients who receive Soliris, you will be provided a card to carry with you, listing specific trigger symptoms. This card is named: Patient Safety Card .</p><p>If you experience any of the following symptoms, you should immediately inform your doctor:</p><ul><li>headache with nausea or vomiting</li><li>headache with a stiff neck or back</li><li>fever</li><li>rash</li><li>confusion</li><li>severe muscle aches combined with flu-like symptoms</li><li>sensitivity to light</li></ul><p>Treatment for meningococcal infection while travelling If you are travelling in a remote region where you are unable to contact your doctor or in which you find yourself temporarily unable to receive medical treatment, your doctor can make arrangements to issue, as a preventive measure, a prescription for an antibiotic to counter Neisseria meningitidis that you keep with you. If you experience any of the symptoms amongst those cited above, you should take the antibiotics as prescribed. You should bear in mind that you should see a doctor as soon as possible, even if you feel better after having taken the antibiotics.</p><p>Infections Before starting Soliris, inform your doctor if you have any infections.</p><p>Allergic reactions Soliris contains a protein and proteins can cause allergic reactions in some people.</p><p>Children and adolescents Patients less than 18 years of age must be vaccinated against Haemophilus influenzae and pneumococcal infections</p><p>Older people There are no special precautions needed for the treatment of patients aged from 65 years and over.</p><p>Other medicines and Soliris Tell your doctor or pharmacist if you are using or have recently used or might use any other medicines.</p><p>Pregnancy, breast-feeding, and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>Women of childbearing potential The use of effective contraception during treatment and up to 5 months after treatment should be considered in women who are able to get pregnant.</p><p>Pregnancy/ Breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. Driving and using machines Soliris has no or negligible influence on the ability to drive and use machines.</p><p>Soliris contains sodium Once diluted with sodium chloride 9 mg/mL (0.9%) solution for injection, this medicine contains 0.88 g sodium (main component of cooking/table salt) in 240 mL at the maximal dose. This is equivalent to 44 % of the recommended maximum daily dietary intake of sodium for an adult. You should take this into consideration if you are on a controlled sodium diet. Once diluted with sodium chloride 4.5 mg/mL (0.45%) solution for injection, this medicine contains 0.67 g sodium (main component of cooking/table salt) in 240 mL at the maximal dose. This is equivalent to 33.5 % of the recommended maximum daily dietary intake of sodium for an adult. You should take this into consideration if you are on a controlled sodium diet.</p></div>"
}
},
{
"title" : "3. How to take soliris",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take soliris"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>At least 2 weeks before you start treatment with Soliris, your doctor will administer a vaccine against meningococcal infection if it was not previously administered or if your vaccination is outdated. If your child is below the age of vaccination or if you are not vaccinated at least 2 weeks before you start treatment with Soliris, your doctor will prescribe antibiotics to reduce the risk of infection until 2 weeks after you have been vaccinated. Your doctor will administer a vaccine to your child aged less than 18 years against Haemophilus influenzae and pneumococcal infections according to the national vaccination recommendations for each age group.</p><p>Instructions for proper use The treatment will be given by your doctor or other health care provider by infusing a dilution of the Soliris vial from a drip bag through a tube directly into one of your veins. It is recommended that the beginning of your treatments, called the initial phase, will extend over 4 weeks, followed by a maintenance phase.</p><p>If you use this medicine to treat PNH For adults: Initial Phase:</p><p>Every week for the first four weeks, your doctor will administer an intravenous infusion of diluted Soliris. Each infusion will consist of a dose of 600 mg (2 vials of 30 ml) and will take 25 45 minutes (35 minutes 10 minutes).</p><p>Maintenance Phase: In the fifth week, your doctor will administer an intravenous infusion of diluted Soliris at a dose of 900 mg (3 vials of 30 ml) over a 25 45 minute (35 minutes 10 minutes) period. After the fifth week, your doctor will administer 900 mg of diluted Soliris every two weeks as a long-term treatment.</p><p>If you use this medicine to treat aHUS, refractory gMG or NMOSD For adults: Initial Phase: Every week for the first four weeks, your doctor will administer an intravenous infusion of diluted Soliris. Each infusion will consist of a dose of 900 mg (3 vials of 30 ml) and will take 25 45 minutes (35 minutes 10 minutes).</p><p>Maintenance Phase: In the fifth week, your doctor will administer an intravenous infusion of diluted Soliris at a dose of 1,200 mg (4 vials of 30 ml) over a 25 45 minute (35 minutes 10 minutes) period. After the fifth week, your doctor will administer 1,200 mg of diluted Soliris every two weeks as a long-term treatment.</p><p>Children and adolescents with PNH, aHUS or refractory gMG and who are 40 kg weight and over are treated with the adult dosing.</p><p>Children and adolescents with PNH, aHUS or refractory gMG and who are under 40 kg weight require a lower dose based on how much they weigh. Your doctor will calculate this.</p><p>For children and adolescents with PNH and aHUS aged less than 18 years: Body Weight Initial Phase Maintenance Phase 30 to <40 kg 600 mg weekly for the first 2 weeks 900 mg at week 3; then 900 mg every 2 weeks 20 to <30 kg 600 mg weekly for the first 2 weeks 600 mg at week 3; then 600 mg every 2 weeks 10 to <20 kg 600 mg weekly single dose at week 1 300 mg at week 2; then 300 mg every 2 weeks 5 to <10 kg 300 mg weekly single dose at week 1 300 mg at week 2; then 300 mg every 3 weeks</p><p>Subjects who undergo plasma exchange may receive additional doses of Soliris.</p><p>Following each infusion, you will be monitored for about one hour. Your doctor s instructions should be carefully observed.</p><p>If you receive more Soliris than you should<br/>If you suspect that you have been accidentally administered a higher dose of Soliris than prescribed, please contact your doctor for advice.</p><p>If you forget an appointment to receive Soliris If you forget an appointment, please contact your doctor immediately for advice and see section below If you stop using Soliris .</p><p>If you stop using Soliris for PNH Interrupting or ending treatment with Soliris may cause your PNH symptoms to come back more severely soon. Your doctor will discuss the possible side effects with you and explain the risks. Your doctor will want to monitor you closely for at least 8 weeks.</p><p>The risks of stopping Soliris include an increase in the destruction of your red blood cells, which may cause:</p><ul><li>A significant fall in your red blood cell counts (anaemia),</li><li>Confusion or change in how alert you are,</li><li>Chest pain, or angina,</li><li>An increase in your serum creatinine level (problems with your kidneys), or</li><li>Thrombosis (blood clotting).<br/>If you have any of these symptoms, contact your doctor.</li></ul><p>If you stop using Soliris for aHUS<br/>Interrupting or ending treatment with Soliris may cause your aHUS symptoms to come back. Your doctor will discuss the possible side effects with you and explain the risks. Your doctor will want to monitor you closely.</p><p>The risks of stopping Soliris include an increase in the inflammation of your platelets, which may cause:</p><ul><li>A significant fall in your platelets (thrombocytopenia),</li><li>A significant rise in destruction of your red blood cells,</li><li>Decreased urination (problems with your kidneys),</li><li>An increase in your serum creatinine level (problems with your kidneys),</li><li>Confusion or change in how alert you are,</li><li>Chest pain, or angina,</li><li>Shortness of breath, or</li><li>Thrombosis (blood clotting).</li></ul><p>If you have any of these symptoms, contact your doctor.</p><p>If you stop using Soliris for refractory gMG<br/>Interrupting or stopping treatment with Soliris may cause your gMG symptoms to come back. Please speak to your doctor before stopping Soliris. Your doctor will discuss the possible side effects and risks with you. Your doctor will also want to monitor you closely. If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse.</p><p>If you stop using Soliris for NMOSD Interrupting or stopping treatment with Soliris may cause your NMOSD to worsen and relapse to happen. Please speak to your doctor before stopping Soliris. Your doctor will discuss the possible side effects and risks with you. Your doctor will also want to monitor you closely.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Your doctor will discuss the possible side effects with you and explain the risks and benefits of Soliris with you prior to treatment. The most serious side effect was meningococcal sepsis. If you experience any of the meningococcal infection symptoms (see section 2 Meningococcal and other Neisseria infections alert), you should immediately inform your doctor.</p><p>If you are not sure what the side effects below are, ask your doctor to explain them to you.</p><p>Very common: may affect more than 1 in 10 people: headache.</p><p>Common: may affect up to 1 in 10 people: infection of the lung (pneumonia), common cold (nasopharyngitis), infection of the urinary system (urinary tract infection),<br/>low white blood cell count (leukopenia), reduction in red blood cells which can make the skin pale and cause weakness or breathlessness inability to sleep dizziness, high blood pressure upper respiratory tract infection, cough, throat pain (oropharyngeal pain), bronchitis, cold sores (herpes simplex) diarrhea, vomiting, nausea, abdominal pain, rash, hair loss (alopecia), itchy skin (pruritus) pain in the joints (arms and legs), pain in the limbs (arms and legs)<br/>fever (pyrexia), feeling tired (fatigue), influenza like illness infusion related reaction</p><p>Uncommon: may affect up to 1 in 100 people: severe infection (meningococcal infection), sepsis, septic shock, viral infection, , lower respiratory tract infection, stomach flu (gastrointestinal infection), cystitis infection, fungal infection, collection of pus (abscess), type of infection of the skin (cellulitis), influenza, sinusitis, tooth infection (abscess), gum infection<br/>relatively few platelets in blood (thrombocytopenia), low level of lymphocytes a specific type of white blood cells (lymphopenia), feeling your heartbeat<br/>serious allergic reaction which causes difficulty in breathing or dizziness (anaphylactic reaction), hypersensitivity loss of appetite depression, anxiety, mood swings, sleep disorder<br/>tingling in part of the body (paresthesia), shaking, taste disorders (dysgeusia), fainting vision blurred ringing in the ears, vertigo sudden and rapid development of extremely high blood pressure, low blood pressure, hot flush, vein disorder<br/>dyspnoea (difficulty breathing), nose bleed, stuffy nose (nasal congestion), throat irritation, runny nose (rhinorrhoea) inflammation of the peritoneum (the tissue that lines most of the organs of the abdomen), constipation, stomach discomfort after meals (dyspepsia), abdominal distension<br/>hives, redness of the skin, dry skin, red or purple spots under the skin, increased sweating, inflammation of the skin muscle cramp, muscle aches, back and neck pain, bone pain kidney disorder, difficulties or pain when urinating (dysuria), blood in urine spontaneous penile erection swelling (edema), chest discomfort, feeling of weakness (asthenia), chest pain, infusion site pain, chills<br/>increase of liver enzymes, decrease of the proportion of blood volume that is occupied by red blood cells, decrease in the protein in red blood cells that carries oxygen</p><p>Rare: may affect up to 1 in 1,000 people: infection by fungi (Aspergillus infection), infection of the joint (arthritis bacterial), Haemophilus influenzae infection, impetigo, bacterial sexual transmitted disease (gonorrhea) skin tumor (melanoma), bone marrow disorder destruction of red blood cells (haemolysis), clumping of cells, abnormal clotting factor, abnormal blood clotting, disease with thyroid overactivity (Basedow s disease) abnormal dreams irritation of eye bruise unusual backflow of food from stomach, gum pain yellowing of the skin and/or eyes (jaundice) skin color disorder spasm of mouth muscle, joint swelling<br/>menstrual disorder abnormal leakage of the infused drug out of the vein, infusion site abnormal sensation, feeling hot</p><p>Reporting of side effects<br/>If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store soliris",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store soliris"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP . The expiry date refers to the last day of that month. Store in a refrigerator (2 C 8 C).<br/>Do not freeze. Soliris vials in the original package may be removed from refrigerated storage for only one single period of up to 3 days. At the end of this period the product can be put back in the refrigerator. Store in the original package in order to protect from light. After dilution, the product should be used within 24 hours.</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Soliris contains</p><p>The active substance is eculizumab (300 mg/30 ml in a vial corresponding to 10 mg/ml).</p><p>The other ingredients are:</p><ul><li>sodium phosphate monobasic</li><li>sodium phosphate dibasic</li><li>sodium chloride</li><li>polysorbate 80 (vegetable origin) Solvent: water for injections</li></ul><p>What Soliris looks like and contents of the pack Soliris is presented as a concentrate for solution for infusion (30 ml in a vial pack size of 1).<br/>Soliris is a clear and colorless solution.</p><p>Marketing Authorisation Holder Alexion Europe SAS 103-105 rue Anatole France 92300 Levallois-Perret France</p><p>Manufacturer Almac Pharma Services 22 Seagoe Industrial Estate Craigavon BT63 5QD United Kingdom</p><p>Alexion Pharma International Operations Limited<br/>College Business and Technology Park Blanchardstown Road North, Dublin D15 RIreland</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien<br/>Alexion Pharma Belgium<br/>T l/Tel: +32 0 800 200 Lietuva<br/>UAB AstraZeneca Lietuva<br/>Tel: +370 5 2660</p><p>Te .: +359 24455Luxembourg/Luxemburg<br/>Alexion Pharma Belgium<br/>T l/Tel: +32 0 800 200 esk republika<br/>AstraZeneca Czech Republic s.r.o.<br/>Tel: +420 222 807 Magyarorsz g<br/>AstraZeneca Kft.<br/>Tel.: +36 1 883 6Danmark<br/>Alexion Pharma Nordics AB<br/>Tlf: +46 0 8 557 727 Malta<br/>Alexion Europe SAS<br/>Tel: +353 1 800 882 Deutschland<br/>Alexion Pharma Germany GmbH<br/>Tel: +49 (0) 89 45 70 91 Nederland<br/>Alexion Pharma Netherlands B.V.<br/>Tel: +32 (0)2 548 36 Eesti<br/>AstraZeneca<br/>Tel: +372 6549 Norge<br/>Alexion Pharma Nordics AB<br/>Tlf: +46 (0)8 557 727<br/>AstraZeneca A.E.<br/>: +30 210 6871 sterreich<br/>Alexion Pharma Austria GmbH<br/>Tel: +41 44 457 40 Espa a<br/>Alexion Pharma Spain, S.L.<br/>Tel: +34 93 272 30 Polska<br/>AstraZeneca Pharma Poland Sp. z o.o.<br/>Tel.: +48 22 245 73 France<br/>Alexion Pharma France SAS<br/>T l: +33 1 47 32 36 Portugal<br/>Alexion Pharma Spain, S.L. - Sucursal em Portugal<br/>Tel: +34 93 272 30 Hrvatska<br/>AstraZeneca d.o.o.<br/>Tel: +385 1 4628 Rom nia<br/>AstraZeneca Pharma SRL<br/>Tel: +40 21 317 60 Ireland<br/>Alexion Europe SAS<br/>Tel: +353 1 800 882 Slovenija<br/>AstraZeneca UK Limited<br/>Tel: +386 1 51 35 sland<br/>Alexion Pharma Nordics AB<br/>S mi: +46 0 8 557 727 Slovensk republika<br/>AstraZeneca AB, o.z.<br/>Tel: +421 2 5737 7Italia<br/>Alexion Pharma Italy srl<br/>Tel: +39 02 7767 9Suomi/Finland<br/>Alexion Pharma Nordics AB<br/>Puh/Tel: +46 0 8 557 727<br/>Alexion Europe SAS<br/>: +357 22490Sverige<br/>Alexion Pharma Nordics AB<br/>Tel: +46 0 8 557 727 Latvija<br/>SIA AstraZeneca Latvija<br/>Tel: +371 67377United Kingdom (Northern Ireland)<br/>Alexion Europe SAS<br/>Tel: +44 (0) 800 028 4This leaflet was last revised in.</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp9290357e39a2371931091ec451b2e152",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp9290357e39a2371931091ec451b2e152",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp9290357e39a2371931091ec451b2e152\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp9290357e39a2371931091ec451b2e152</b></p><a name=\"mp9290357e39a2371931091ec451b2e152\"> </a><a name=\"hcmp9290357e39a2371931091ec451b2e152\"> </a><a name=\"mp9290357e39a2371931091ec451b2e152-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/393/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Soliris 300 mg concentrate for solution for infusion</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/07/393/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Soliris 300 mg concentrate for solution for infusion",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
